This website is intended only for United States healthcare professionals; if you are not a United States healthcare professional, please visit www.BioMarin.com
This website was developed and funded by BioMarin and is intended for healthcare professionals only. It offers a non-exhaustive selection of materials, including but not limited to publications, presentations, posters and educational materials, to support scientific exchange.
Clinical study results reflect knowledge at the study’s completion and may not be current. Review the methodology, limitations, and authors’ financial disclosures for details.
The information on this website is not medical advice and should not replace independent medical judgment or further research. Content on investigational therapeutics or uses of approved products does not confirm safety or efficacy. BioMarin does not endorse off-label use of its medicines.
As product information may vary by country, please refer to your local health authority regulations and respective approved product information for indications and safety details.

Clinical Program

Learn about phenylketonuria clinical trials and research at BioMarin

Visit the BioMarin Clinical Trials website

Phenylketonuria Pipeline

Search/Filter
Filter by phase:
Filter by status:

Metabolic Conditions

Trial phase

Program (Trial)
Condition
Phase

Pegvaliase

(165-401 [IMPALA])

Trial Status Recruiting

Condition

Phenylketonuria

Phase

  • Phase 4

Title

Immune Modulation During Palynziq Treatment in Adults (IMPALA)

Study Description

The overall objective of the study is to evaluate the ability of methotrexate (MTX), when co-administered with Palynziq, to suppress immune responses to Palynziq and thus improve the tolerability and efficacy of Palynziq in adults with phenylketonuria (PKU).

Primary Outcome Measures*

  • To evaluate blood phenylalanine (Phe) response in adults with PKU co-administered Palynziq with MTX for 6 months
  • To evaluate the ability of MTX to modulate the immune response to Palynziq in adults with PKU

Select Inclusion Criteria*

  • Adults between 18 and 65 years old
  • Have a confirmed diagnosis of PKU
  • Are willing and medically eligible to receive Palynziq and MTX Cohort A: Have never taken Palynziq before and are willing to start it during the study Cohort B: Have blood >600 μmol/L after taking Palynziq for at least 24 weeks, are on a daily dose of at least 20 mg and unable to increase the dose further

Secondary Outcome Measures*

  • To evaluate the safety of co-administration of Palynziq with MTX in adults with PKU. A treatment-emergent adverse event (TEAE) is defined as any adverse event (AE) that newly appeared, increased in frequency, or worsened in severity following initiation of the study drugs (MTX or Palynziq) administration. Incidence of TEAEs will be defined as (number of TEAEs)/(total exposure time in person-years) *100
  • To characterize the pharmacokinetics (PK) of Palynziq during co-administration with MTX in adults with PKU

Select Exclusion Criteria*

  • Have a serious active infection or a history of severe or recurrent infections
  • Have a history of substance or alcohol abuse within the past 12 months
  • Have had an organ transplant or are taking chronic immunosuppressive medications
  • Are using, or plan to use, injectable PEG-containing medications other than Palynziq during the study

* Additional measures/criteria may apply.

For reference and comprehensive trial information, visit ClinicalTrials.gov NCT07477691

Pegvaliase

(165-501[PALace])

Trial Status Recruiting

Condition

Phenylketonuria

Phase

  • Phase 4

Title

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

Study Description

This is a 10-year multicenter, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union [EU] only) in subjects receiving pegvaliase for the treatment of PKU.

Primary Outcome Measures*

  • To quantify and characterize the risk of protocol-defined safety events in incident-users receiving pegvaliase for the treatment of PKU in a real-world setting

Select Inclusion Criteria*

  • Documented diagnosis of PKU per local standard of care
  • Receiving or plan to receive pegvaliase treatment within 30 days of enrollment

Secondary Outcome Measures*

  • To quantify and characterize the risk of protocol-defined safety events in subjects receiving pegvaliase for the treatment of PKU in a real-world setting

Select Exclusion Criteria*

  • Subject has any kind of disorder that may compromise the ability of the subject to give written informed consent
  • Currently participating in an interventional study of any investigational product, device, or procedure

* Additional measures/criteria may apply.
PKU, phenylketonuria.

For reference and comprehensive trial information, visit ClinicalTrials.gov NCT05813678

Pegvaliase

(165-503 [PALisade])

Trial Status Recruiting

Condition

Phenylketonuria

Phase

  • Phase 4

Title

A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

Study Description

This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US).

Primary Outcome Measures*

  • Immunologic and inflammatory responses associated with occurrences of: acute systemic hypersensitivity reaction, anaphylaxis, angioedema, serum sickness, severe hypersensitivity reaction, severe or persistent arthralgia, severe injection site reaction

Select Inclusion Criteria*

  • Enrolled at US sites participating in the 165-501 (PALace) study.

Secondary Outcome Measures*

  • Immunologic and inflammatory responses (immunologic testing, inflammatory markers) associated with occurrences of end-organ function (e.g., kidney, liver) related, immune-mediated adverse drug reactions
  • The potential association between immunologic responses and blood Phe levels

Select Exclusion Criteria*

  • Legal incapacity or limited legal capacity without legal guardian representation
  • Subject is unable or unwilling to provide informed consent for the additional interventional burden of the study (blood sampling)

* Additional measures/criteria may apply.

For reference and comprehensive trial information, visit ClinicalTrials.gov NCT06305234

Pegvaliase

(165-504 [PALomino])

Trial Status Recruiting

Condition

Phenylketonuria

Phase

  • Phase 4

Title

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding (PALomino)

Study Description

This is a Phase 4 observational study designed to assess the impact of Palynziq® (pegvaliase) treatment in pregnant women with PKU and on their offspring who were exposed to pegvaliase at any time during pregnancy and breastfeeding.

Primary Outcome Measures*

  • Pregnancy outcome and infant development for women who have been treated with Palynziq (pegvaliase) within 2 weeks of their last menstrual period

Select Inclusion Criteria*

  • Subject or legal guardian consent
  • Confirmation of ongoing pregnancy
  • Diagnosed with PKU

Secondary Outcome Measures*

  • Pregnancy outcomes
  • Serious adverse events
  • Maternal pegvaliase use during breastfeeding

Select Exclusion Criteria*

  • Currently participating in a BioMarin-sponsored interventional study

* Additional measures/criteria may apply.
PKU, phenylketonuria.

For reference and comprehensive trial information, visit ClinicalTrials.gov NCT05579548

Pegvaliase

(165-306 [PEGASUS])

Trial Status Active, Not Recruiting

Condition

Phenylketonuria

Phase

  • Phase 3

Title

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria (PEGASUS)

Study Description

This is a Phase 3, open-label, randomized, controlled study enrolling approximately 54 adolescents with PKU. The study is designed to assess the safety and efficacy of pegvaliase injections.

Primary Outcome Measures*

  • Change in blood Phe concentration
  • Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0

Select Inclusion Criteria*

  • Must be 12 to 17 years old
  • Signed informed consent

Secondary Outcome Measures*

  • Change in total dietary protein intake

Select Exclusion Criteria*

  • Previous treatment with pegvaliase
  • Use of any medication that is intended to treat PKU within 14 days prior to administration

* Additional measures/criteria may apply.
CTCAE v5.0, Common Terminology Criteria for Adverse Events version 5.0; Phe, phenylalanine; PKU, phenylketonuria.

For reference and comprehensive trial information, visit ClinicalTrials.gov NCT05270837